IPM Take
Anti-amyloid treatment has made Alzheimer’s biology measurable in a new way. The uncomfortable next question is whether medicine is measuring the right thing.
A longitudinal study of patients receiving lecanemab in routine clinical care found dozens of plasma proteins changed during treatment, but the biomarkers associated with amyloid clearance were largely different from those associated with later cognitive change. That does not weaken the rationale for anti-amyloid therapy. It explains why removing pathology and preserving function are related but not interchangeable outcomes.
Executive Summary
The Lancet Neurology longitudinal cohort study followed people with early symptomatic Alzheimer’s disease receiving lecanemab through the Washington University Memory Diagnostic Center.
Researchers analysed 130 plasma proteins and compared patterns associated with treatment, amyloid PET conversion and cognitive change. The wider dataset included 1,967 participants, while 197 patients receiving lecanemab formed the treated clinical cohort. Among treated patients, 34 measured proteins changed significantly with increasing treatment exposure.
Critically, proteins associated with amyloid clearance were largely distinct from those associated with subsequent cognitive decline. The study therefore suggests that future blood monitoring may need to measure several biological processes rather than rely on a single marker as a universal measure of whether treatment is “working.”
This was an observational study from a single clinical centre and has not yet been externally validated across broader populations.
Why it matters
- Patients increasingly ask a reasonable question after months of Alzheimer’s treatment: Is it working for me? At present, clinicians can confirm amyloid reduction, but that does not provide a simple individual forecast for memory, function or future decline.
- The study begins to separate those questions biologically. One group of biomarkers may indicate successful amyloid removal; another may better reflect the processes associated with cognitive trajectory. If replicated, that distinction could eventually change treatment monitoring and help clinicians move beyond a binary model of giving or stopping therapy.
Alzheimer’s treatment has entered an era where the disease can be measured with extraordinary precision and still remain difficult to explain to the person sitting in front of the clinician.
Lecanemab removes amyloid. That biological effect is established. What remains much harder is translating the amount of amyloid removed into an individual answer about how quickly memory, reasoning and daily function will change. The new longitudinal data from Washington University help explain why.
Across a broad plasma-protein panel, researchers found that lecanemab treatment triggered multiple biological changes. Some markers tracked with amyloid clearance. Others were more closely associated with cognitive trajectories. They were largely not the same markers.
That matters because Alzheimer’s care is at risk of replacing one simplification with another. For years, clinical diagnosis had too little biology. The field now has the opposite danger: assuming that one well-measured biological process can tell the whole clinical story.
A future monitoring strategy may therefore need several layers: amyloid removal, tau biology, neurodegeneration, inflammation and markers related to synaptic function. The objective should not be to generate more laboratory numbers for their own sake. It should be to answer the question patients actually ask: what is happening to my disease?
For health systems, that creates another infrastructure challenge. Personalised treatment monitoring sounds attractive, but increasingly complex biomarker panels require validated laboratories, interpretation standards and evidence showing that acting on those results improves outcomes.
Alzheimer’s medicine is getting better at watching biology move. It now needs to learn which movements matter most to the person.
